entasis
therapeutics
participate
upcoming
healthcare
investor
conferences
waltham
globe
newswire
entasis
therapeutics
holdings
nasdaq
ettx
biopharmaceutical
company
focused
discovery
development
novel
antibacterial
products
today
announced
manos
perros
president
chief
executive
officer
company
present
virtually
wainwright
annual
global
investment
conference
september
cantor
virtual
global
healthcare
conference
september
oppenheimer
fall
healthcare
life
sciences
medtech
summit
september
wainwright
nd
annual
global
investment
conference
date
tuesday
september
time
pm
et
cantor
virtual
global
healthcare
conference
date
thursday
september
time
et
link
https
webcast
page
oppenheimer
fall
healthcare
life
sciences
medtech
summit
date
tuesday
september
time
pm
et
replay
cantor
presentation
available
company
website
days
following
event
additionally
perros
hold
virtual
investor
meetings
conferences
investors
attending
conferences
virtually
interested
meeting
company
management
contact
wainwright
cantor
oppenheimer
representatives
entasis
entasis
biopharmaceutical
company
focused
discovery
development
commercialization
novel
antibacterial
products
treat
serious
infections
caused
bacteria
entasis
design
platform
produced
pipeline
product
candidates
including
targeting
acinetobacter
baumannii
infections
zoliflodacin
targeting
neisseria
gonorrhoeae
infections
targeting
enterobacteriaceae
infections
targeting
pseudomonas
infections
information
visit
entasis
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
plan
anticipate
estimate
intend
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
based
entasis
expectations
assumptions
date
press
release
statements
involves
risks
uncertainties
actual
results
may
differ
materially
statements
many
factors
may
cause
differences
current
expectations
actual
results
including
unexpected
safety
efficacy
data
observed
clinical
studies
clinical
site
activation
rates
clinical
trial
enrollment
rates
lower
expected
changes
expected
existing
competition
changes
regulatory
environment
failure
entasis
collaborators
support
advance
collaborations
product
candidates
unexpected
litigation
disputes
many
factors
beyond
entasis
control
risks
uncertainties
described
fully
entasis
filings
securities
exchange
commission
including
section
titled
risk
factors
contained
therein
statements
contained
announcement
made
date
except
required
law
entasis
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
entasis
company
contact
kyle
dow
entasis
therapeutics
investor
relations
contacts
james
salierno
ruth
group
jsalierno
